Consultant / Business Development Manager
Sepia Molecular Holdings Gmbh
Gera, Thuringia, Germany
SMH strategically targets high unmet clinical needs in Cancer, and Infectious diseases (such as COVID-19), where Fast Track and Breakthrough Designation is likely. This allows product development with smaller, trials and commercialisation using small sales forces servicing specialist hospital physicians, reducing development, regulatory and commercialisation costs and speeding up access to the market.SMH’s general value creation policy is to develop its own products and to partner/ license its larger indication products at late-stage for final development or commercialisation. However, where terms are financially acceptable, SMH will contemplate earlier licensing, co-development and or co-promotion of its products, globally or in specific markets.SMH has teamed up with academic institutions to expedite the development of the siRNA and DNA-technology platforms to treat cancer and infectious diseases. This industry-university collaboration channels rapid transfer of results from the forefront of academic scientific research to focused development of smart medication relying on the vast industrial know-how of the pharmaceutical industry.